These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 949520)
1. Urinary pseudouridine and beta-aminoisobutyric acid in patients with low grade urothelial tumours. Relations between excretion and tumour recurrence. Nyholm KK; Sjolin KE; Wolf H; Hammer M; Knudsen J; Stahl D; Nielsen HR Biomedicine; 1976 May; 25(3):85-7. PubMed ID: 949520 [TBL] [Abstract][Full Text] [Related]
2. Pseudouridine and beta-aminoisobutyric acid excretion in urine: diagnostic and prognostic value. Kvist E; Sjølin KE Scand J Urol Nephrol; 1990; 24(4):283-5. PubMed ID: 2274752 [TBL] [Abstract][Full Text] [Related]
3. Excretion patterns of pseudouridine and beta-aminoisobutyric acid in patients with tumours of the upper urinary tract. Kvist E; Sjølin KE; Iversen J Scand J Urol Nephrol; 1990; 24(4):287-92. PubMed ID: 2274753 [TBL] [Abstract][Full Text] [Related]
4. A study on the clinical significance of urinary beta-aminoisobutyric acid in patients with urothelial tumours. Nyholm KK; Sjölin KE; Hammer M; Knudsen J; Stahl D; Nielsen HR Biomedicine; 1975 Nov; 22(6):509-16. PubMed ID: 1225382 [TBL] [Abstract][Full Text] [Related]
5. Relationship between urinary beta-aminoisobutyric acid and transfer RNA turnover in cancer patients. Nielsen HR; Nyholm K; Sjolin KE Cancer Res; 1974 Dec; 34(12):3428-32. PubMed ID: 4429961 [No Abstract] [Full Text] [Related]
6. Urinary excretion of beta-aminoisobutyrate and pseudouridine in acute and chronic myeloid leukemia. Nielsen HR; Killmann SA J Natl Cancer Inst; 1983 Nov; 71(5):887-91. PubMed ID: 6580488 [TBL] [Abstract][Full Text] [Related]
7. Beta-aminoisobutyric acid in urine from patients with urothelial tumours. Nielsen HR; Nyholm K; Sjölin KE Rev Eur Etud Clin Biol; 1971 May; 16(5):444-50. PubMed ID: 5113307 [No Abstract] [Full Text] [Related]
8. Urinary excretion patterns of pseudouridine and beta-aminoisobutyric acid in patients with tumours of the urinary bladder. Kvist E; Sjølin KE; Iversen J; Nyholm K Scand J Urol Nephrol; 1993; 27(1):45-53. PubMed ID: 8493467 [TBL] [Abstract][Full Text] [Related]
9. Pseudouridine: a prognostic marker in non-Hodgkin's lymphomas. Rasmuson T; Björk GR Cancer Detect Prev; 1985; 8(1-2):287-90. PubMed ID: 4064048 [TBL] [Abstract][Full Text] [Related]
10. Correlations of beta-aminoisobutyric acid in 8 hour and 24 hour urinary samples determined by dual column gas chromatography. Sjölin KE; Nyholm KK Biomedicine; 1980 May; 32(2):60-5. PubMed ID: 7388117 [TBL] [Abstract][Full Text] [Related]
11. Nucleoside excretion in breast cancer: comparison with other biochemical tumour-index-substances. Coombes RC; Powles TJ; Gehrke CW; Waalkes TP; Neville AM Invest Cell Pathol; 1979; 2(1):11-4. PubMed ID: 511604 [TBL] [Abstract][Full Text] [Related]
12. Pseudouridine excretion in patients with psoriasis. Clemmensen OJ; Kieffer M; Sjølin KE Acta Derm Venereol; 1987; 67(4):310-4. PubMed ID: 2445149 [TBL] [Abstract][Full Text] [Related]
13. [Interrelationship of pseudouridine and transfer RNA metabolic disorders in thermal injury]. Salomatin VV; Efimenko GP; Kamilov FKh; Lifshits RI Vopr Med Khim; 1977; 23(5):642-6. PubMed ID: 595499 [TBL] [Abstract][Full Text] [Related]
14. Biochemically detectable tumor markers in urine of bladder cancer patients. Irving CC Cancer Res; 1977 Aug; 37(8 Pt 2):2872-4. PubMed ID: 872116 [TBL] [Abstract][Full Text] [Related]
15. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas. Rasmuson T; Björk GR Cancer Detect Prev; 1983; 6(1-2):293-6. PubMed ID: 6883387 [TBL] [Abstract][Full Text] [Related]
16. Urinary pseudouridine as a biochemical marker in the diagnosis and monitoring of primary hepatocellular carcinoma. Tamura S; Fujioka H; Nakano T; Amuro Y; Hada T; Nakao N; Higashino K Am J Gastroenterol; 1988 Aug; 83(8):841-5. PubMed ID: 2456010 [TBL] [Abstract][Full Text] [Related]
17. [Pseudouridine and uric acid excretion in patients with viral hepatitis]. Lifshits RI; Salomatin VV; Efimenko GP Vopr Med Khim; 1976; 22(5):687-90. PubMed ID: 1014482 [TBL] [Abstract][Full Text] [Related]
18. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. Solsona E; Iborra I; Rubio J; Casanova J; Almenar S BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101 [TBL] [Abstract][Full Text] [Related]
19. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Li CC; Chang TH; Wu WJ; Ke HL; Huang SP; Tsai PC; Chang SJ; Shen JT; Chou YH; Huang CH Eur Urol; 2008 Nov; 54(5):1127-34. PubMed ID: 18243511 [TBL] [Abstract][Full Text] [Related]